Summary of findings 7. Probiotics versus placebo for treating collagenous colitis.
| Probiotics versus placebo for treating collagenous colitis | ||||||
| Patient or population: Patients with collagenous colitis Setting: Outpatients Intervention: Probiotics Comparison: Placebo | ||||||
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | № of participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Risk with placebo | Risk with Probiotics | |||||
| Clinical response | 125 per 10001 | 286 per 1000 (40 to 1000) | RR 2.29 (0.32 to 16.13) | 29 (1 RCT) | ⊕⊝⊝⊝ very low2,3 | |
| Adverse events | 500 per 10001 | 285 per 1000 (110 to 750) | RR 0.57 (0.22 to 1.50) | 29 (1 RCT) | ⊕⊝⊝⊝ very low3,4 | |
| *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | ||||||
1 Control group risk comes from control arm of the included study. 2 Downgraded two levels due to very sparse data and wide confidence interval (7 events). 3 Downgraded one level due to unclear risk of bias for allocation concealment. 4 Downgraded two levels due to very sparse data and wide confidence interval (10 events).